View all the latest information in
acute myeloid leukemia
, arranged by trials and clinical studies. Listed below are recently added trial updates.
Prognostic significance of concomitant gene mutations in intensively treated patients with IDH1/2-mutated AML
At the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation,...
The benefit of gemtuzumab ozogamicin in patients with AML depends on mutational status and level of CD33 expression
A study evaluating whether molecular events could predict the benefit of adding...
LDAC plus AC220: Results from the LI-1 trial in older patients with AML
During the 25th European Hematology Association (EHA) Annual Congress 2020, Mike Dennis presented an oral abstract on the...
Editorial theme | The value of FLT3 targeting in AML
FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed by hematopoietic stem and progenitor cells and is involved in the early...
Molecular landscape and prognostic impact of FLT3-ITD insertion site in AML: An analysis of the RATIFY study
During an oral abstract session at the Virtual Edition of the 25th European Hematology...
EHA 2019 round up – FLT3 mutations in AML
Last year, at the European Hematology Association (EHA) meeting, a lot of attention was focused on the FMS-like tyrosine kinase-3 (FLT3) mutations in acute...
AML Hub Satellite Symposium: How does MRD impact outcome of stem cell transplantation in AML, now and in the future?
At the 46th Annual Meeting of the European Society for Blood and Marrow...
AML18 trial: How should gemtuzumab ozogamicin be applied in AML?
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Nigel Russell, Guy's and St Thomas' NHS...